New research reveals that people who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight at a significantly accelerated pace than those who end conventional lifestyle plans.
Published data in a prominent health publication points out that while obese individuals often shed about a fifth of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Individuals buying these drugs need to be cognizant of the risk of fast weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to starting weight within about one and a half years.
Analyzing Treatments
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
Scientists point out that people who lose weight through diet and exercise usually experience a more gradual creep back—around 100 grams monthly—after stopping.
Understanding the Quick Regain
Doctors propose the mode of action of the drugs explains the accelerated regain.
The injections imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of the hormone levels several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating far more likely."
A Lifelong Issue?
Medical guidelines suggest the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Professionals say that, due to the significant potential of relapse, the treatment is often life-long.
This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the chronic character of excess weight," similar to managing diseases like hypertension.
User Accounts
Individuals who have stopped the medication describe a intense return of hunger.
"It was like a trigger that goes on and I was suddenly starving," recalled a patient.
This difficulty is exacerbated if patients have not developed sustainable dietary or behavioural changes during treatment.
Growing Use
Recent estimates show that millions of adults in the UK have tried these injections in the past year, with desire remaining high.
- Use is more common among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent fix and lasting health benefits hinges on integrated behavioural management.
